Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Hsu

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Journal of Neuro-Oncology|April 7, 2006
Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)T S Armstrong, T Mendoza, I Gning, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 21, 2012
The role of SHIP in the development and activation of mouse mucosal and connective tissue mast cellsJens Ruschmann, Frann Antignano, Vivian Lam, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2002
Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremiaNancy Shulman, Andrew Zolopa, Diane Havlir, et al.
CNS Drugs|April 21, 2015
Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension TrialCheryl H Waters, Paul Nausieda, Lyudmila Dzyak, et al.
Journal of Parkinson'S Disease|October 8, 2015
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical TrialsPaul A Nausieda, Ann Hsu, Lawrence Elmer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 15, 2011
Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's diseaseRobert A Hauser, Aaron L Ellenbogen, Leo Verhagen Metman, et al.
RMD Open|May 13, 2020
Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisAlexis Ogdie, Kurt de Vlam, Iain B McInnes, et al.
RMD Open|February 5, 2019
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugsVibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, et al.
Arthritis Research & Therapy|October 31, 2018
Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of diseasePhilip Helliwell, Laura C Coates, Oliver FitzGerald, et al.
Blood Cells, Molecules & Diseases|July 29, 2019
Combined genetic disruption of K-Cl cotransporters and Gardos channel KCNN4 rescues erythrocyte dehydration in the SAD mouse model of sickle cell diseaseBoris E Shmukler, Alicia Rivera, Parul Bhargava, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Journal of Neuro-Oncology|April 7, 2006
Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)T S Armstrong, T Mendoza, I Gning, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 21, 2012
The role of SHIP in the development and activation of mouse mucosal and connective tissue mast cellsJens Ruschmann, Frann Antignano, Vivian Lam, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2002
Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremiaNancy Shulman, Andrew Zolopa, Diane Havlir, et al.
CNS Drugs|April 21, 2015
Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension TrialCheryl H Waters, Paul Nausieda, Lyudmila Dzyak, et al.
Journal of Parkinson'S Disease|October 8, 2015
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical TrialsPaul A Nausieda, Ann Hsu, Lawrence Elmer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 15, 2011
Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's diseaseRobert A Hauser, Aaron L Ellenbogen, Leo Verhagen Metman, et al.
RMD Open|May 13, 2020
Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisAlexis Ogdie, Kurt de Vlam, Iain B McInnes, et al.
RMD Open|February 5, 2019
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugsVibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, et al.
Arthritis Research & Therapy|October 31, 2018
Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of diseasePhilip Helliwell, Laura C Coates, Oliver FitzGerald, et al.
Blood Cells, Molecules & Diseases|July 29, 2019
Combined genetic disruption of K-Cl cotransporters and Gardos channel KCNN4 rescues erythrocyte dehydration in the SAD mouse model of sickle cell diseaseBoris E Shmukler, Alicia Rivera, Parul Bhargava, et al.
Pageof 7